These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18057188)

  • 41. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A semi-separable utility function for health profiles.
    Guerrero AM; Herrero C
    J Health Econ; 2005 Jan; 24(1):33-54. PubMed ID: 15617787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
    Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
    J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index.
    Dan AA; Kallman JB; Srivastava R; Younoszai Z; Kim A; Younossi ZM
    Liver Transpl; 2008 Mar; 14(3):321-6. PubMed ID: 18306356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Being there is important, but getting there matters too: the role of path in the valuation process.
    Goldberg JH
    Med Decis Making; 2006; 26(4):323-37. PubMed ID: 16855122
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A note on the nature of utility in time and health and implications for cost utility analysis.
    Buckingham KJ; Devlin NJ
    Soc Sci Med; 2009 Jan; 68(2):362-7. PubMed ID: 19019518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.
    Kawakami S; Numao N; Okubo Y; Koga F; Yamamoto S; Saito K; Fujii Y; Yonese J; Masuda H; Kihara K; Fukui I
    Eur Urol; 2008 Sep; 54(3):601-11. PubMed ID: 18207312
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes.
    Hoerger TJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S21-7. PubMed ID: 19536014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health state utility scores in advanced non-small cell lung cancer.
    Doyle S; Lloyd A; Walker M
    Lung Cancer; 2008 Dec; 62(3):374-80. PubMed ID: 18467000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessing health state utilities in elderly patients at cardiovascular risk.
    Winkelmayer WC; Benner JS; Glynn RJ; Schneeweiss S; Wang PS; Brookhart MA; Levin R; Jackson JD; Avorn J
    Med Decis Making; 2006; 26(3):247-54. PubMed ID: 16751323
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The predictive validity of prospect theory versus expected utility in health utility measurement.
    Abellan-Perpiñan JM; Bleichrodt H; Pinto-Prades JL
    J Health Econ; 2009 Dec; 28(6):1039-47. PubMed ID: 19833400
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Elicitation of informed general population health state utility values: a review of the literature.
    McTaggart-Cowan H
    Value Health; 2011 Dec; 14(8):1153-7. PubMed ID: 22152187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validity and interpretation of preference-based measures of health-related quality of life.
    Lenert L; Kaplan RM
    Med Care; 2000 Sep; 38(9 Suppl):II138-50. PubMed ID: 10982099
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A meta-analysis of utility estimates for HIV/AIDS.
    Tengs TO; Lin TH
    Med Decis Making; 2002; 22(6):475-81. PubMed ID: 12458977
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate?
    Pullenayegum EM; Tarride JE; Xie F; Goeree R; Gerstein HC; O'Reilly D
    Value Health; 2010; 13(4):487-94. PubMed ID: 20230549
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development and validation of a utility weighting function for the patient-oriented prostate utility scale (PORPUS).
    Tomlinson G; Bremner KE; Ritvo P; Naglie G; Krahn MD
    Med Decis Making; 2012; 32(1):11-30. PubMed ID: 21653804
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Time-tradeoff utilities for identifying and evaluating a minimum data set for time-critical biosurveillance.
    Doctor JN; Baseman JG; Lober WB; Davies J; Kobayashi J; Karras BT; Fuller S
    Med Decis Making; 2008; 28(3):351-8. PubMed ID: 18480039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry.
    Jeong CW; Cowan JE; Broering JM; Ten Ham RMT; Wilson LS; Carroll PR; Cooperberg MR
    Eur Urol; 2019 Dec; 76(6):743-751. PubMed ID: 31345635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.